Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Senate Banking Committee Could Pave the Way to a Bankable Marijuana Industry
New York, New York (NetworkNewsWire) - Last month, a letter signed by 10 U.S. senators arrived on the desk of Jamal El-Hindi, the acting director of the Financial Crimes Enforcement Network (FinCEN), requesting guidance on how banking services might be offered to "indirect businesses" - such as SinglePoint, Inc. (OTC: SING), Medical Marijuana, Inc. (OTC: MJNA) and Cannabis Science, Inc. (OTC: CBIS) - that serve the state-sanctioned marijuana industry. The implications of such guidance also carry considerable potential for banking players ranging from small financial institutions to bellwether banks like Bank of America (NYSE: BAC) and Citigroup (NYSE: C).
The letter came at the prompting of U.S. Senator Elizabeth Warren, D-Mass, a member of the Senate Banking Committee that oversees federal monetary policy, banking regulation and issues affecting the U.S. currency. It's a widely applauded push, and SinglePoint, Inc., for one, is banking on this initiative to clear the way for payment processing providers, such as its SingleSeed Payments subsidiary, to offer an array of payment and transaction services to marijuana shops and dispensaries.
According to a recent report in the Houston Chronicle (http://nnw.fm/qq6NB), this action is part of a wider effort by many policymakers to regularize the patchwork legal nature of the $7 billion marijuana industry, marked by a lack of banking options that forces marijuana businesses "to rely solely on cash, making them tempting targets for criminals."
Although 28 states and the District of Columbia have now legalized either adult recreational or medical use of marijuana, the Drug Enforcement Administration (DEA) still classifies it as a Schedule I substance "with no currently accepted medical use and a high potential for abuse." Yet, there is growing evidence in the medical profession and the general population that marijuana has beneficent therapeutic properties.
Companies like Cannabis Science, Inc. have set out to develop novel cannabinoid-based therapies for unmet medical needs, while others like Medical Marijuana, Inc. - the first publicly traded cannabis company - focuses on a variety of cannabinoid-based applications for consumer and medical markets.
In a collection of 60 peer-reviewed studies on medical marijuana (http://nnw.fm/75PYw) examining the employment of marijuana in the treatment of a long list of ailments - including amyotrophic lateral sclerosis (ALS), cancer and HIV/AIDS - 41 (68.3%) demonstrated positive results. Another 14 (23.3%) were inconclusive, and five (8.3%) of the trials reported negative outcomes.
Senator Warren has argued that loosening the restrictions that force marijuana businesses to transact in cash payments has a number of advantages.
"You make sure that people are really paying their taxes. You know that the money is not being diverted to some kind of criminal enterprise. And it's just a plain old safety issue. You don't want people walking in with guns and masks and saying, 'Give me all your cash.'"
There is some hope that the barriers preventing payment services providers like SingleSeed from doing business with marijuana establishments will be removed. FinCEN previously lent a sympathetic ear to similar pleas. In February 2014, the bureau offered guidance on how financial institutions could provide services to marijuana-related businesses consistent with their Bank Secrecy Act obligations.
That earlier guidance appears to have been tailored to businesses that dealt directly in marijuana like pot shops and marijuana dispensaries. It did not address the plight of the indirect businesses that service the marijuana industry, leaving it up to individual financial institutions to determine how to classify and treat indirect businesses.
Tossing the buck to financial institutions has had paltry success: "the number of banks and credit unions willing to handle pot money rose from 51 in 2014 to 301 in 2016," a figure that appears encouraging until placed in a wider context. There are 11,954 federally regulated banks and credit unions. In general, it's still an area dominated by small state-chartered banks and credit unions. Supporters of a bankable marijuana industry, however, see an inevitable day when large banks like Bank of America and Citigroup will offer full banking services to the cannabis industry.
When that day comes, financial technology (fintech) companies will have the chance to capitalize on a monstrous opportunity. SinglePoint's SingleSeed Payments subsidiary, for example, is already primed to offer ATM, Pay-by-Text™ and text message marketing to the cannabis industry. As it stands, progressive fintechs are in a similar quandary to their federally regulated counterparts and look forward to further guidance from FinCEN.
SinglePoint is a state-of-the-art mobile technology and full-service mobile marketing company specializing in acquisitions of small to mid-sized companies, with a particular focus on mobile technologies.
includes acquisitions of minority investments in two separate daily fantasy sports (DFS) enterprises, GoDraft and DraftFury. In the second half of the year, SinglePoint signed a funding agreement with Blackbridge Capital, LLC for up to $3 million in equity financing to fund the Company's acquisition strategy and expedite its current trek toward uplisting to the OTCQB. In November, following the legalization of recreational marijuana and medical cannabis, SinglePoint announced the accelerated strategies of its SingleSeed (www.singleseed.com) payments business to provide credit card processing solutions for the cannabis industry.
After briefly touching on SinglePoint's aggressive acquisition strategy, the report also discusses SinglePoint's Pay-by-Text and Text2Bid platforms, as well as opportunities within the multi-billion dollar mobile payments, fantasy sports and cannabis markets.
forecasting revenues of $2.6 million in 2017, $6.2 million in 2018, and $9.8 million in 2018, as well as a turn to profit on an EBITDA basis in 2018.
$SING
https://www.insiderfinancial.com/viaderma-inc-otcmktsvdrm-is-a-big-news-runner/119107/
TetraStem to one of the following: fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. When one of these gets underway from a clinical development perspective, that’s when the positive news stream will really start flowing, and in turn, that’s when we’ll see this one pull out of the double zeros.
VDRM Market Value $3M a/o Jan 17, 2017
OWCP Market Value $97M a/o Jan 17, 2017
---------->>>>>>>>>
$VDRM $OWCP
Another strong NEWS !!!
Strong NEWS !!!!
OWC* - 0.90 - 125M Market Value
VDRM - 0.019 - 5M Market Value
... ->>>>>>>
$VDRM $OWCP
Viaderma Inc is exploring the possibility of licensing the technology to other pharmaceutical companies. It has products in development in various fields, including topical antibiotics (TetraStem), topical anti-viral product (Viralcur) for genital herpes, anti-fungal products for onychomycocis (OnyPro), hair loss prevention product (HairGain), skin cancer therapies (Cantrile), and a topical stem cell therapy product (TetraStem Plus).
$VDRM
Viaderma Inc is a pharmaceutical company focused on bringing new products to the pharmaceutical industry through research and development. With that, it licenses and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. The company’s products are distributed over-the-counter and are applied topically using a delivery system technology.
Aside from developing and selling new products to the market, Viaderma Inc is exploring the possibility of licensing the technology to other pharmaceutical companies. It has products in development in various fields, including topical antibiotics (TetraStem), topical anti-viral product (Viralcur) for genital herpes, anti-fungal products for onychomycocis (OnyPro), hair loss prevention product (HairGain), skin cancer therapies (Cantrile), and a topical stem cell therapy product (TetraStem Plus).
VDRM
ViaDerma, Inc. Enters the (MMJ) or Medical Marijuana industry with a Patent Pending CBD Delivery System as California Votes for Expanded Uses of Cannabis
Nov 14, 2016
OTC Disclosure & News Service
-
ViaDerma, Inc. Enters the (MMJ) or Medical Marijuana industry with a Patent Pending CBD Delivery System as California Votes for Expanded Uses of Cannabis
The Treatment Success of ViaDerma's Proprietary Delivery System for Several Diseases by the Efficient and Effective Transdermal Delivery of CBD's & THC to the Localized Treatment Area & into the Blood Stream
LOS ANGELES, CA--(Marketwired - November 14, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.
On November 8th, medical and recreational marijuana was passed in several states that voted on medical marijuana provisions, in what is turning out to be, the biggest electoral victory for marijuana reform since 2012. The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.
ViaDerma also has Viabecline, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.
Market for the following Drugs:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema- $2.5 billion in 2014
ViaDerma sees the use of CBD's along with our Proprietary transdermal delivery system for the treatment and continuing studies look very promising and demonstrate efficacy in terms of treating several unrelated diseases. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Christopher Otiko, ViaDerma's founder and CEO.
iHub NewsWire
Two Licensing Deals for ViaDerma's FDA Registered Viabecline is with two Pharmaceutical Companies Biogenx and Chemo-Pharma, Ltd.
Biogenx
http://earthgrid.com/biogenx/biogenx.html
Chemo-Pharma, Ltd
http://www.chemopharma.com/
LOCATIONS AUSTRIA (HQ) BELARUS BULGARIA CZECH REPUBLIC POLAND RUSSIA SERBIA TURKEY
operating in Central, Eastern and South-Eastern Europe
With affiliates and representing offices in various COUNTRIES, we guarantee short communication paths whilst providing excellent customer service.
http://www.chemopharma.com/contact/
Potential Markets 25B year
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema- $2.5 billion in 2014
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management.
25B year (Without including the potential markets mentioned)
Authorized Shares 400,000,000 a/o Dec 30, 2016
Outstanding Shares 262,319,103 a/o Dec 30, 2016
-Restricted 66,981,278 a/o Dec 30, 2016
-Unrestricted 195,337,825 a/o Dec 30, 2016
Held at DTC 133,325,809 a/o Dec 30, 2016
Float 51,061,509 a/o Jun 30, 2016
Beneficial owners.
Provide a list of the name, address and shareholdings of all persons beneficially owning more than five percent (5%)
of any class of the issuer's equity securities as of September 30, 2016.
Dr. Chris Ayo Otiko................ 44,000,000 21.96% (CEO)
Greentree Financial Group Inc.......12,000,000 5.99%
Maurice Katz 295.................... 8,507,017 4.25%
$VDRM
Authorized Shares 400,000,000 a/o Dec 30, 2016
Outstanding Shares 262,319,103 a/o Dec 30, 2016
-Restricted 66,981,278 a/o Dec 30, 2016
-Unrestricted 195,337,825 a/o Dec 30, 2016
Held at DTC 133,325,809 a/o Dec 30, 2016
Float 51,061,509 a/o Jun 30, 2016
Beneficial owners.
Provide a list of the name, address and shareholdings of all persons beneficially owning more than five percent (5%)
of any class of the issuer's equity securities as of September 30, 2016.
Dr. Chris Ayo Otiko................ 44,000,000 21.96% (CEO)
Greentree Financial Group Inc.......12,000,000 5.99%
Maurice Katz 295.................... 8,507,017 4.25%
$VDRM
ViaDerma, Inc. Enters the (MMJ) or Medical Marijuana industry with a Patent Pending CBD Delivery System as California Votes for Expanded Uses of Cannabis
Nov 14, 2016
OTC Disclosure & News Service
-
ViaDerma, Inc. Enters the (MMJ) or Medical Marijuana industry with a Patent Pending CBD Delivery System as California Votes for Expanded Uses of Cannabis
The Treatment Success of ViaDerma's Proprietary Delivery System for Several Diseases by the Efficient and Effective Transdermal Delivery of CBD's & THC to the Localized Treatment Area & into the Blood Stream
LOS ANGELES, CA--(Marketwired - November 14, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.
On November 8th, medical and recreational marijuana was passed in several states that voted on medical marijuana provisions, in what is turning out to be, the biggest electoral victory for marijuana reform since 2012. The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.
ViaDerma also has Viabecline, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.
Market for the following Drugs:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema- $2.5 billion in 2014
ViaDerma sees the use of CBD's along with our Proprietary transdermal delivery system for the treatment and continuing studies look very promising and demonstrate efficacy in terms of treating several unrelated diseases. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Christopher Otiko, ViaDerma's founder and CEO.
Two Licensing Deals for ViaDerma's FDA Registered Viabecline is with two Pharmaceutical Companies Biogenx and Chemo-Pharma, Ltd.
Biogenx
http://earthgrid.com/biogenx/biogenx.html
Chemo-Pharma, Ltd
http://www.chemopharma.com/
LOCATIONS AUSTRIA (HQ) BELARUS BULGARIA CZECH REPUBLIC POLAND RUSSIA SERBIA TURKEY
operating in Central, Eastern and South-Eastern Europe
With affiliates and representing offices in various COUNTRIES, we guarantee short communication paths whilst providing excellent customer service.
http://www.chemopharma.com/contact/
Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema- $2.5 billion in 2014
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management.
25B year (Without including the potential markets mentioned)
NEWS !!!!!!
VDRM
NEWS
On January 31, 2014, the Company purchased an exclusive license (the "License") on the patent pending technology from Dr. Howard Phillips represented by US Patent #20130190274. The Company amended the License on September 30, 2016 such that it is now a non-exclusive distribution and licensing agreement.
Viabecline is currently listed with the FDA. Detailed product information is available online by accessing the Government website, DailyMed.
p.7
http://www.otcmarkets.com/financialReportViewer?symbol=VDRM&id=164573
US Patent #20130190274
January 31, 2014, purchased patent pending technology from
Dr. Howard Phillips by US Patent #20130190274
https://twitter.com/Akingwasborn91/status/814144631172714497
https://twitter.com/Akingwasborn91/status/814151896780984320
vdrm
Revenues climbed 47 times or 4757% FACT
Revenues climbed from $1,755 to $83,500 for the 3 months ended September 30. Up 47 times more or 4757%
VDRM
bid 9.7M
Par Share Count: 1,450,000,000.00 Authorized Shares
Par Share Count: 50,000,000.00
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=Hl5NakkHa2WAYIQE7gyj2A%253d%253d&nt7=0
File Date: 12/9/2016 Effective Date:
Previous Stock Value: Par Value Shares: 950,000,000 Value: $ 0.001 Par Value Shares: 50,000,000 Value: $ 0.001 No Par Value Shares: 0 ----------------------------------------------------------------- Total Authorized Capital: $ 1,000,000.00 New Stock Value: Par Value Shares: 1,450,000,000 Value: $ 0.001 Par Value Shares: 50,000,000 Value: $ 0.001 No Par Value Shares: 0 ----------------------------------------------------------------- Total Authorized Capital: $ 1,500,000.00
http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=Hl5NakkHa2WAYIQE7gyj2A%253d%253d&CorpName=MOMENTOUS+ENTERTAINMENT+GROUP+INC
relax :)
strong ""Slap the ask!" :)
I tried it and it was delivered.
http://www.viadermalicensing.com/
Phone: 310-496-5744 | Fax: 310-943-1457
info@viadermalicensing.com
sales@viadermalicensing.com
Following empty discussions with Merck (MRK) last week in San Diego, Peregrine Pharmaceuticals (PPHM) now working to partner with ViaDerma (VDRM) for the application of bavituximab utilizing VDRM's cutting edge delivery system technology predicts Sierra World Equity Review
Following empty discussions with Merck (MRK) last week in San Diego, Peregrine Pharmaceuticals (PPHM) now working to partner with ViaDerma (VDRM) for the application of bavituximab utilizing VDRM's cutting edge delivery system technology predicts Sierra World Equity Review. While big pharma Pfizer (PFE) looks set to acquire ViaDerma (VDRM) any partnership PPHM has ongoing with VDRM will be magnified by PFE involvement forecasts Sierra. Check back as Sierra's man on the ground, Adam travels to Tustin to work his sources!
http://sierraworldequityreview.blogspot.com
$VDRM
The costs of sales represent less than 4% of total sales.
Until September, sales were 209K; The cost of sales was 8k.
The company earned an operating profit of 27K.
Operating expenses are on average 57K per quarter.
Extrapolating, what was said by the CEO in the interview on Friday, December 9.
It expects sales in 2017 of 1M and double that amount in 2018 to the 2M.
Then we will have in 2017:
1M sales
40K cost of sales
960K Sales Profit
Operating costs 228K
Operating profit of 732K
/ 225M shares = 0.0032 earnings per share
In 2018:
2M sales
Cost of sales 80K
Profit from sales 1,920M
Operating costs 228K
Operating profit of 1.692M
/ 225M shares = 0.00752 earnings per share
__________________________________________________________________
(Taking for example the company MJN*: has negative operating results of 1M per quarter and has a capitalization of 338M)
Is here .. listen
December 9, 2016
Podcast
http://upticknewswire.com/viaderma-ceo-dr-chris-otiko-talks-active-treatments-for-diabetic-wounds/
In negotiating with 3 companies; One of them is a technology company..
I heard right?
ViaDerma CEO, Dr. Chris Otiko, talks Active Treatments for Diabetic Wounds
December 9, 2016
Podcast
http://upticknewswire.com/viaderma-ceo-dr-chris-otiko-talks-active-treatments-for-diabetic-wounds/
1M Sales 2017
2M Sales 2018 ?
Did I hear right??
Someone places the interview here, please.
Uptick Newswire |ViaDerma CEO, Dr. Chris Otiko, talks Active ...
https://upticknewswire.com/viaderma-ceo-dr-chris-otiko-talks-acti...
1 day ago - ViaDerma CEO, Dr. Chris Otiko, talks Active Treatments for Diabetic Wounds ... Everett Jolly Interviews Dr. Chris Otiko, CEO for ViaDerma, Inc. (VDRM), and they ...
https://upticknewswire.com/viaderma-ceo-dr-chris-otiko-talks-active-treatments-for-diabetic-wounds/
(Is that I can not access, I still do not understand why.)
DEC 9, 2016
ViaDerma CEO, Dr. Chris Otiko, talks Active Treatments for Diabetic Wounds
Everett Jolly Interviews Dr. Chris Otiko, CEO for ViaDerma, Inc. (VDRM), and they discuss their products that treat diabetic wounds. — visit https://upticknewswire.com for more Interviews and the ...
https://upticknewswire.newswire.com/browse/blog
Uptick Newswire |ViaDerma CEO, Dr. Chris Otiko, talks Active ...
https://upticknewswire.com/viaderma-ceo-dr-chris-otiko-talks-acti...
1 day ago - ViaDerma CEO, Dr. Chris Otiko, talks Active Treatments for Diabetic Wounds ... Everett Jolly Interviews Dr. Chris Otiko, CEO for ViaDerma, Inc. (VDRM), and they ...
https://upticknewswire.com/viaderma-ceo-dr-chris-otiko-talks-active-treatments-for-diabetic-wounds/
(I can not open this, I do not know why.)
ViaDerma CEO, Dr. Chris Otiko, talks Active Treatments for Diabetic Wounds ... Everett Jolly Interviews Dr. Chris Otiko, CEO for ViaDerma, Inc. (VDRM) 1 day ago - yesterday 12/09
Share structure unchanged
Confirmed today by TA
Authorized Shares 400,000,000 a/o Nov 28, 2016
Outstanding Shares 225,319,103 a/o Nov 28, 2016
-Restricted 66,981,278 a/o Nov 28, 2016
-Unrestricted 158,337,825 a/o Nov 28, 2016
Held at DTC 133,325,809 a/o Nov 28, 2016
Float 51,061,509 a/o Jun 30, 2016
Dear xxxx,
Please refer to OTCmarkets.com for the share structure of VDRM.
Best Regards,
ClearTrust Operations Team
just a curiosity:
On otcmarkets shows: Outstanding Shares 381,721,575 a / o Dec 06, 2016
But in Latest Report May 31, 2016 10-Q shows: As of May 31, 2016 there were 3,862,296,184 shares of common stock
Does anyone know the reason for this?
Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema- $2.5 billion in 2014
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management.
not 19.7 but 25B (Without including the potential markets mentioned)
Good research work.
Smith & Nephew plc (ADR) Mkt cap 12.49B
Cash and Short Term Investments 85.00M